159 related articles for article (PubMed ID: 36794339)
1. Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review.
Gao S; Li Y; He Z; Zhu J; Liang D; Yang S; Mo J; Lam K; Yu X; Huang M; Wu J
Expert Opin Drug Saf; 2023; 22(7):599-609. PubMed ID: 36794339
[TBL] [Abstract][Full Text] [Related]
2. Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data.
Yan MM; Wu SS; Qi YP; Li ZR; Zhang Q; Zhao H; Zhong MK; Qiu XY
Expert Opin Drug Saf; 2022 Feb; 21(2):277-283. PubMed ID: 34581647
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
Breast Cancer Res Treat; 2021 Feb; 186(1):219-227. PubMed ID: 33150548
[TBL] [Abstract][Full Text] [Related]
4. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
5. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
6. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
West MT; Smith CE; Kaempf A; Kohs TCL; Amirsoltani R; Ribkoff J; Choung JL; Palumbo A; Mitri Z; Shatzel JJ
Eur J Haematol; 2021 May; 106(5):634-642. PubMed ID: 33527479
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.
Di Lauro V; Barchiesi G; Martorana F; Zucchini G; Muratore M; Fontanella C; Arpino G; Del Mastro L; Giuliano M; Puglisi F; De Laurentiis M
ESMO Open; 2022 Dec; 7(6):100629. PubMed ID: 36399953
[TBL] [Abstract][Full Text] [Related]
8. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Fusaroli M; La Placa M; Ardizzoni A; Zamagni C; Poluzzi E; De Ponti F
Am J Clin Dermatol; 2022 Mar; 23(2):247-255. PubMed ID: 34699032
[TBL] [Abstract][Full Text] [Related]
9. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
10. Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System.
Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917020
[TBL] [Abstract][Full Text] [Related]
11. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
12. Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors: A real-world study of data from the food and drug administration adverse event reporting system database.
Ren X; Yan C; Tian L; Cui X
Int J Immunopathol Pharmacol; 2022; 36():3946320221145520. PubMed ID: 36565299
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
Gervaso L; Montero AJ; Jia X; Khorana AA
J Thromb Haemost; 2020 Jan; 18(1):162-168. PubMed ID: 31479568
[TBL] [Abstract][Full Text] [Related]
14. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.
Onesti CE; Jerusalem G
Expert Rev Anticancer Ther; 2021 Mar; 21(3):283-298. PubMed ID: 33233970
[No Abstract] [Full Text] [Related]
15. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
Thein KZ; Htut TW; Ball S; Swarup S; Sultan A; Oo TH
Breast Cancer Res Treat; 2020 Sep; 183(2):479-487. PubMed ID: 32647939
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network.
She Y; Guo Z; Zhai Q; Liu J; Du Q; Zhang Z
Front Pharmacol; 2024; 15():1378090. PubMed ID: 38633610
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
18. Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer.
Watson NW; Wander SA; Shatzel JJ; Al-Samkari H
Cancer; 2022 Sep; 128(17):3224-3232. PubMed ID: 35767226
[TBL] [Abstract][Full Text] [Related]
19. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
[TBL] [Abstract][Full Text] [Related]
20. Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer.
Cejuela M; Gil-Torralvo A; Castilla MÁ; Domínguez-Cejudo MÁ; Falcón A; Benavent M; Molina-Pinelo S; Ruiz-Borrego M; Salvador Bofill J
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
